In this podcast, JNIS Editor-in-Chief, Dr. Felipe C. Albuquerque, speaks with Dr. Marco Colasurdo (1) and Prof. Dheeraj Gandhi (2), authors of the original research article, "Predictors for large vessel recanalization before stroke thrombectomy: the HALT score" - https://jnis.bmj.com/content/early/2023/04/25/jnis-2023-020220

This paper is free-to-access for a month following the publication of this podcast. 

Please subscribe to the JNIS Podcast via all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify, to get the latest episodes. Also, please consider leaving us a review or a comment on the JNIS Podcast iTunes page: https://podcasts.apple.com/gb/podcast/jnis-podcast/id942473767 

Thank you for listening! This episode was edited by Brian O'Toole. 

(1) Interventional Neuroradiology, Dept. of Diagnostic Radiology, Uni. of Maryland Medical Center, Baltimore, Maryland, USA 
(2) Dept. of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut, USA

Predictors for large vessel recanalization before stroke thrombectomy: the HALT score

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Ramez N. Eskander to discuss NRG-018 pembrolizumab and chemotherapy in uterine cancer. Dr. Eskander is a gynecologic oncologist who specializes in the comprehensive management of female reproductive system cancers, including ovarian, uterine, cervical, vulvar and vaginal cancer. His expertise includes diagnostic and therapeutic procedures, including minimally invasive (robotic) surgery, chemotherapy and novel drugs.

Highlights:

• NRG-GY018 showed that the addition of pembrolizumab to chemotherapy, followed by maintenance pembrolizumab, resulted in a 70% lower risk of disease progression or death in patients in the dMMR cohort and a 46% lower risk in the pMMR cohort than in the placebo group.

• These data suggest that the incorporation of immunotherapy into the first-line treatment of advanced or recurrent endometrial cancer improves oncologic outcomes, regardless of MMR status or histologic findings.

• Previous monotherapy drugs against PD-1 and PD-L1 in recurrent or metastatic pMMR endometrial cancer resulted in only modest improvement.

NRG-018 Pembrolizumab and Chemotherapy in Uterine Cancer with Ramez Eskander

Dr Kerry Costello and Dr Deepak Kumar discuss a BSJM paper that investigated gait and physical activity predictors of cartilage worsening in people with knee osteoarthritis from the MOST study, using a machine learning model. Kerry and Deepak do a brilliant job of explaining the biomechanical variables, and the advantages of machine learning, and what these findings might mean for clinicians treating people with knee osteoarthritis. 

Link to paper: https://bjsm.bmj.com/content/early/2023/03/02/bjsports-2022-106142
Connect with Kerry: https://mae.ufl.edu/people/faculty/primary/profiles/kerry-costello/

Quantity AND Quality Is Key For People With Knee OA – Dr Kerry Costello And Dr Deepak Kumar. EP#531

Editor-in-Chief of the Archives of Disease in Childhood, Dr. Nick Brown, and Senior Editor of ADC, Dr. Rachel Agbeko, bring you the monthly Atoms - the highlights of the June 2023 issue.
Read it on the Archives of Disease in Childhood website: https://adc.bmj.com/content/108/6/i
Please listen to our regular podcasts and subscribe in Apple Podcasts, Google Podcasts, Stitcher and Spotify to get episodes automatically downloaded to your phone and computer. And if you enjoy the podcast, please leave us a review at https://podcasts.apple.com/gb/podcast/adc-podcast/id333278832

Atoms: the highlights from the ADC June 2023

In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the June 2023 issue of DTB. They discuss new guidelines on post-exposure prophylaxis
for varicella or shingles during pregnancy (https://dtb.bmj.com/content/61/6/82). They review the effect of low-dose aspirin on fractures and falls (https://dtb.bmj.com/content/61/6/85), and talk about a study that does not provide meaningful cardiovascular outcome data for inclisiran (https://dtb.bmj.com/content/61/6/86). The main review article explores hospitalisation as a consequence of medication-related harm and the need to reduce the burden of harm caused by medication (https://dtb.bmj.com/content/61/6/87). They begin by discussing an announcement from NHS England that antibiotics will be provided without the need for a prescription from community pharmacies to free up GP time.

The contact address for the DTB team is dtb@bmj.com.
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.

Aciclovir PEP after VZ exposure in pregnancy, falls and fractures with aspirin, an inclisiran rant

Dr Philip Smith, Digital and Education Editor of Gut and Honorary Consultant Gastroenterologist at the Royal Liverpool Hospital, Liverpool, UK interviews Professor Kathy DelGiorno, from the Department of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee, USA, on the paper 'It is better to light a candle than to curse the darkness: single-cell transcriptomics sheds new light on pancreas biology and disease' published in paper copy in Gut in June 2023 and available online: https://gut.bmj.com/content/72/6/1211

Please subscribe to the Gut Podcast via all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify, to get the latest podcast every month. If you enjoy our podcast, please consider leaving us a review or a comment on the Gut Podcast iTunes page (https://podcasts.apple.com/gb/podcast/gut-podcast/id330976727).

Single-cell transcriptomics sheds new light on pancreas biology and disease

A summary of some of the best paper we published in the June 2023 issue of the Emergency Medicine Journal. Rick and Sarah talk through topics including home pulse oximetry, out of hospital cardiac arrest, the perils of correctly calculating respiratory rate in the ED and even cross-cultural adaptation of patient communication material.

Read the highlights: https://emj.bmj.com/content/40/6/393

You can subscribe to the EMJ podcast via all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify, to get the latest podcast every month.
If you enjoy our podcast, please consider leaving us a review or a comment on the EMJ Podcast iTunes page (https://podcasts.apple.com/us/podcast/emj-podcast/id445358244). 
Thank you for listening!

Primary Survey - the highlights of June 2023

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Diego Raimondo and Giulia Rovero. 

Dr. Raimondo works as medical director and assistant researcher at the Division of Gynecology and Pathophysiology of Human Reproduction, Bologna, Italy, directed by Prof. Renato Seracchioli. He received his PhD on new technologies for endometriosis surgical removal from the University of Bologna in 2021. He is an Advisory Board Member of the ESGE (European Society for Gynaecological Endoscopy) and member of the Special Interest Group in Robotics. His research interests are focused on minimally invasive surgery (laparoscopic, robotic and hysteroscopic) for endometriosis and endometrial cancer. 

Dr. Giulia Rovero graduated in Medicine in 2017 at the University of Florence. She is currently a fifth-year resident at the Division of Gynecology and Pathophysiology of Human Reproduction, Bologna, Italy, directed by Prof. Renato Seracchioli. In 2022/23 she spent twelve months at the Lariboisiere Hospital in Paris focusing on gynecologic oncology. She is developing her research activity in collaboration with Dr. Raimondo in the field of minimally invasive surgery for endometrial cancer. 

Highlights:

* In endometrial carcinoma (EC) patients, the rate of sentinel lymph node (SLN) mapping failure ranges from 20% to 25%.
* Pooled data assessing predictive factors of SLN mapping failure in EC patients undergoing SLN biopsy through the cervical injection of indocyanine green (ICG) are lacking.
* ICG dose <3mL, advanced FIGO stage, lymph node involvement and bulky lymph node are predictive factors of SLN mapping failure in EC patients.
* Neither clinical features (i.e., BMI >30 kg/m2, menopausal status, adenomyosis) nor surgical history is significantly associated with SLN mapping failure in EC patients.
* Deep myometrial invasion, FIGO grade 3, non-endometrioid histotype, and lymphovascular space invasion are not significantly associated with SLN mapping failure in EC patients.

Predictors of SLN Mapping Failure with Diego Raimondo and Giulia Rovero

Following on from the recommendations in the paper 'Effective delivery of Complex Innovative Design (CID) cancer trials - a consensus statement', the ECMC Programme Office and the Health Research Authority have collaborated to produce a set of podcasts to inform and educate a range of stakeholders on the common questions around the management and delivery of CID trials. These podcasts have been designed for anyone with an interest in working on or reviewing CID trials. They are presented by experienced researchers, patients, ethic committee chair and members of the HRA.

Hear about what a ‘Complex Innovative Design (CID) trial is and why we should do them. You’ll hear examples of what is meant by a CID trial; the benefits of this method and the challenges they do pose.
Speaker: Professor Pam Kearns, Professor of Clinical Paediatric Oncology, Director of the Cancer Research UK Clinical Trials Unit and Institute of Genomic Sciences in Birmingham

Podcast 2. What Is A Complex Innovative Design And Why Do Them

NHS Health Research Authority

Related tracks